Last reviewed · How we verify
Matching Placebo (twice daily)
Matching placebo has no active pharmacological mechanism; it is an inert control formulation used in clinical trials.
At a glance
| Generic name | Matching Placebo (twice daily) |
|---|---|
| Sponsor | Grünenthal GmbH |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Matching placebo is a pharmaceutical preparation designed to be identical in appearance, taste, and administration schedule to the active investigational drug, but contains no active pharmaceutical ingredient. It serves as a control arm in randomized controlled trials to account for placebo effect and natural disease progression. The twice-daily dosing schedule matches the active comparator to maintain blinding.
Approved indications
Common side effects
Key clinical trials
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis (PHASE1, PHASE2)
- Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection (PHASE2)
- Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis (PHASE2)
- RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (PHASE2)
- HEALEY ALS Platform Trial - Master Protocol (PHASE2, PHASE3)
- OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps (PHASE3)
- Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) (PHASE2)
- Human Laboratory Study of Apremilast for Alcohol Use Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |